---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033349"
form_type: "8-K"
ticker: "HYPR"
cik: "0001833769"
company_name: "Hyperfine, Inc."
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T07:12:36.750130+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Hyperfine promotes Tom Teisseyre to COO; CMO/CSO Siddiqui moves to part-time

## Summary
- Tom Teisseyre (formerly CPO) appointed COO effective July 24, 2023; base salary $425K, target bonus 50%, option grant of 200K shares.
- Khan Siddiqui transitions to 20% part-time CMO/CSO; salary reduced to $87,360/year; removed from Severance Plan.
- Severance Plan amended to remove Siddiqui; remaining participants include CEO, CFO, and Teisseyre.
- Teisseyre will oversee product design, clinical science, operations, cybersecurity, and technical service.

## SEC filing metadata
- accession: 0000950170-23-033349
- form_type: 8-K
- ticker: HYPR
- cik: 0001833769
- company_name: Hyperfine, Inc.
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833769/000095017023033349/0000950170-23-033349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833769/000095017023033349/hypr-20230717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033349
- JSON: https://secwatch.observer/filing/0000950170-23-033349.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033349.txt

## Key facts
- Executive change
  Khan Siddiqui changed role as Chief Medical Officer and Chief Strategy Officer at Hyperfine, Inc..
  - Action: modified
  - Role: Chief Medical Officer and Chief Strategy Officer
  source text: the Company entered into a schedule and salary modification letter agreement (the “Modification Agreement”) with Khan Siddiqui, M.D., the Company’s Chief Medical Officer and Chief Strategy Officer, effective July 24, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833769/000095017023033349/0000950170-23-033349-index.htm
- Executive change
  Thomas Teisseyre was appointed as Chief Operating Officer at Hyperfine, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: Thomas Teisseyre, Ph.D., the Company’s Chief Product Officer, has been appointed by the Board of Directors of the Company (the “Board”) to serve as Chief Operating Officer of the Company, effective as of July 24, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833769/000095017023033349/0000950170-23-033349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.